US4842868A
(en)
*
|
1986-09-26 |
1989-06-27 |
Helwing Robert F |
Covalently bonded active agents with carbonium ion base groups
|
US5214132A
(en)
*
|
1986-12-23 |
1993-05-25 |
Kyowa Hakko Kogyo Co., Ltd. |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
IE64284B1
(en)
*
|
1987-08-03 |
1995-07-26 |
Ddi Pharmaceuticals |
Conjugates of superoxide dismutase
|
CA1308377C
(en)
*
|
1987-08-21 |
1992-10-06 |
Henry Berger, Jr. |
Complex of polyethyleneglycol and tissue plasminogen activator
|
JPH079429B2
(ja)
*
|
1988-10-12 |
1995-02-01 |
財団法人化学及血清療法研究所 |
人工担体およびその製造方法
|
US5091176A
(en)
*
|
1988-11-02 |
1992-02-25 |
W. R. Grace & Co.-Conn. |
Polymer-modified peptide drugs having enhanced biological and pharmacological activities
|
US5306500A
(en)
*
|
1988-11-21 |
1994-04-26 |
Collagen Corporation |
Method of augmenting tissue with collagen-polymer conjugates
|
US5510418A
(en)
*
|
1988-11-21 |
1996-04-23 |
Collagen Corporation |
Glycosaminoglycan-synthetic polymer conjugates
|
US5565519A
(en)
*
|
1988-11-21 |
1996-10-15 |
Collagen Corporation |
Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
|
US5162430A
(en)
*
|
1988-11-21 |
1992-11-10 |
Collagen Corporation |
Collagen-polymer conjugates
|
EP0395918A3
(de)
*
|
1989-04-13 |
1991-10-23 |
Vascular Laboratory, Inc. |
Plasminogen-Aktivatorkomplex von reiner Pro-Urokinase, kovalent gebunden durch eine Disulfidbrücke an menschlichem Serumalbumin
|
AU651949B2
(en)
*
|
1989-07-14 |
1994-08-11 |
American Cyanamid Company |
Cytokine and hormone carriers for conjugate vaccines
|
US5767072A
(en)
*
|
1989-09-14 |
1998-06-16 |
Board Of Regents, The University Of Texas System |
Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
US6652863B1
(en)
|
1992-11-16 |
2003-11-25 |
Centocor, Inc. |
Method of reducing the immunogenicity of compounds
|
CA2150956A1
(en)
*
|
1992-12-10 |
1994-06-23 |
Robert G. L. Shorr |
Glycolipid enzyme-polymer conjugates
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
ES2174915T3
(es)
*
|
1993-11-10 |
2002-11-16 |
Enzon Inc |
Productos de conjugacion mejorados de un interferon con un polimero.
|
US6458762B1
(en)
|
1994-03-28 |
2002-10-01 |
Baxter International, Inc. |
Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
|
EP0773975A4
(de)
*
|
1994-08-04 |
1998-06-10 |
Gordon George Wallace |
Leitfähige elektroaktive biomaterialien
|
US5738846A
(en)
*
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US5770577A
(en)
*
|
1994-11-14 |
1998-06-23 |
Amgen Inc. |
BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
|
MX9704137A
(es)
*
|
1994-12-07 |
1997-09-30 |
Novo Nordisk As |
Polipeptidos de alergenicidad reducida.
|
US5695760A
(en)
*
|
1995-04-24 |
1997-12-09 |
Boehringer Inglehiem Pharmaceuticals, Inc. |
Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
|
US6428790B1
(en)
*
|
1995-04-27 |
2002-08-06 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
|
US6458889B1
(en)
|
1995-12-18 |
2002-10-01 |
Cohesion Technologies, Inc. |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
US6833408B2
(en)
*
|
1995-12-18 |
2004-12-21 |
Cohesion Technologies, Inc. |
Methods for tissue repair using adhesive materials
|
US7883693B2
(en)
*
|
1995-12-18 |
2011-02-08 |
Angiodevice International Gmbh |
Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
|
EP1704878B1
(de)
*
|
1995-12-18 |
2013-04-10 |
AngioDevice International GmbH |
Quervernetzte Polymerzusammensetzungen und Verfahren zu ihrer Verwendung
|
BR9510676A
(pt)
*
|
1995-12-29 |
1999-11-23 |
Procter & Gamble |
Composições detergentes compreendendo enzinas imobilizadas
|
US6106828A
(en)
*
|
1996-02-15 |
2000-08-22 |
Novo Nordisk A/S |
Conjugation of polypeptides
|
CA2242488A1
(en)
*
|
1996-02-15 |
1997-08-21 |
Novo Nordisk A/S |
Conjugation of polypeptides
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
EP0932390A1
(de)
*
|
1996-10-11 |
1999-08-04 |
Sequus Pharmaceuticals, Inc. |
Therapeutische liposomenzusammensetzung und verfahren
|
US6416756B1
(en)
|
1997-01-10 |
2002-07-09 |
Novozymes A/S |
Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
|
JPH10276776A
(ja)
*
|
1997-04-07 |
1998-10-20 |
Toyobo Co Ltd |
可逆的に不活化された耐熱性dnaポリメラーゼ
|
EP1075511A1
(de)
*
|
1998-05-08 |
2001-02-14 |
University Of Southern California |
Grössenveränderte fibrinolytische enzyme
|
JP3839667B2
(ja)
*
|
1998-06-08 |
2006-11-01 |
エフ.ホフマン−ラ ロシュ アーゲー |
慢性C型肝炎の処置のためのPeg−INF−アルファ及びリバビリンの使用
|
US6461849B1
(en)
|
1998-10-13 |
2002-10-08 |
Novozymes, A/S |
Modified polypeptide
|
TWI242000B
(en)
*
|
1998-12-10 |
2005-10-21 |
Univ Southern California |
Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
|
US7303760B2
(en)
*
|
1999-04-23 |
2007-12-04 |
Alza Corporation |
Method for treating multi-drug resistant tumors
|
DK1173222T3
(da)
|
1999-04-23 |
2007-01-29 |
Alza Corp |
Konjugat med en spaltelig binding til brug i et liposom
|
US7238368B2
(en)
*
|
1999-04-23 |
2007-07-03 |
Alza Corporation |
Releasable linkage and compositions containing same
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
WO2001004287A1
(en)
*
|
1999-07-07 |
2001-01-18 |
Maxygen Aps |
A method for preparing modified polypeptides
|
US6423666B1
(en)
|
1999-10-05 |
2002-07-23 |
Bio-Rad Laboratories, Inc. |
Large-pore chromatographic beads prepared by suspension polymerization
|
US6413507B1
(en)
|
1999-12-23 |
2002-07-02 |
Shearwater Corporation |
Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
|
ES2327606T3
(es)
|
2000-01-10 |
2009-11-02 |
Maxygen Holdings Ltd |
Conjugados de g-csf.
|
ES2325877T3
(es)
|
2000-02-11 |
2009-09-23 |
Bayer Healthcare Llc |
Moleculas de tipo factor vii o viia.
|
US7829074B2
(en)
|
2001-10-18 |
2010-11-09 |
Nektar Therapeutics |
Hydroxypatite-targeting poly(ethylene glycol) and related polymers
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
WO2002074806A2
(en)
|
2001-02-27 |
2002-09-26 |
Maxygen Aps |
New interferon beta-like molecules
|
GB0123232D0
(en)
*
|
2001-09-26 |
2001-11-21 |
Smith & Nephew |
Polymers
|
CA2461292A1
(en)
*
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
CA2490360A1
(en)
|
2002-06-21 |
2003-12-31 |
Novo Nordisk Health Care Ag |
Pegylated factor vii glycoforms
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
AU2003285200A1
(en)
*
|
2002-11-09 |
2004-06-03 |
Nobex Corporation |
Modified carbamate-containing prodrugs and methods of synthesizing same
|
US20040219214A1
(en)
*
|
2002-12-30 |
2004-11-04 |
Angiotech International Ag |
Tissue reactive compounds and compositions and uses thereof
|
EP2181704B1
(de)
*
|
2002-12-30 |
2015-05-06 |
Angiotech International Ag |
Wirkstofffreisetzung von schnell gelierender Polymerzusammensetzung
|
US20040151766A1
(en)
*
|
2003-01-30 |
2004-08-05 |
Monahan Sean D. |
Protein and peptide delivery to mammalian cells in vitro
|
GB0305989D0
(en)
*
|
2003-03-15 |
2003-04-23 |
Delta Biotechnology Ltd |
Agent
|
WO2005035565A1
(en)
|
2003-10-10 |
2005-04-21 |
Novo Nordisk A/S |
Il-21 derivatives
|
EP2641611A3
(de)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Kombinationstherapie
|
BRPI0507169A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
US20100028995A1
(en)
*
|
2004-02-23 |
2010-02-04 |
Anaphore, Inc. |
Tetranectin Trimerizing Polypeptides
|
ZA200609638B
(en)
*
|
2004-04-21 |
2008-02-27 |
Alza Corp |
Polymer conjugate releasable under mild thiolytic conditions
|
CN101080246A
(zh)
|
2004-04-28 |
2007-11-28 |
安希奥设备国际有限责任公司 |
用于形成交联生物材料的组合物和系统及关联的制备方法与用途
|
JP2008503217A
(ja)
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
新規抗原結合ポリペプチド及びそれらの使用
|
CA2581093C
(en)
|
2004-09-17 |
2014-11-18 |
Angiotech Biomaterials Corporation |
Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
|
EP1836314B1
(de)
|
2004-12-22 |
2012-01-25 |
Ambrx, Inc. |
Modifiziertes menschliches wachstumshormon
|
US20060188498A1
(en)
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
EP1893632B1
(de)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
|
US20090018029A1
(en)
|
2005-11-16 |
2009-01-15 |
Ambrx, Inc. |
Methods and Compositions Comprising Non-Natural Amino Acids
|
RU2008145084A
(ru)
|
2006-05-24 |
2010-06-27 |
Ново Нордиск Хелс Кеа Аг (Ch) |
Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
|
JP5840345B2
(ja)
|
2006-09-08 |
2016-01-06 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用
|
KR20090091145A
(ko)
|
2006-10-27 |
2009-08-26 |
웨이-치앙 션 |
지질화된 인터페론 및 이의 용도
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
EP2195333A1
(de)
*
|
2007-09-12 |
2010-06-16 |
Anaphore, Inc. |
Auf hsp70 basierende behandlung von autoimmunkrankheiten
|
MX2010004400A
(es)
|
2007-10-23 |
2010-05-20 |
Nektar Therapeutics |
Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos.
|
JP2011502520A
(ja)
*
|
2007-11-09 |
2011-01-27 |
アナフォア インコーポレイテッド |
疾患治療のためのマンノース結合レクチンの融合タンパク質
|
DK2217265T3
(en)
|
2007-11-20 |
2017-07-03 |
Ambrx Inc |
Modified insulin polypeptides and their use
|
CN103694337B
(zh)
|
2008-02-08 |
2016-03-02 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
EP3225248B1
(de)
|
2008-07-23 |
2023-06-07 |
Ambrx, Inc. |
Modifizierte bovine g-csf-polypeptide und ihre verwendung
|
KR101732054B1
(ko)
|
2008-09-26 |
2017-05-02 |
암브룩스, 인코포레이티드 |
비천연 아미노산 복제 의존성 미생물 및 백신
|
AU2009296397B2
(en)
|
2008-09-26 |
2012-11-08 |
Ambrx Inc. |
Modified animal erythropoietin polypeptides and their uses
|
EP2379585A2
(de)
|
2008-10-10 |
2011-10-26 |
Anaphore, Inc. |
Trail-r1 und trail-r2 bindende polypeptide
|
WO2010080720A2
(en)
*
|
2009-01-12 |
2010-07-15 |
Nektar Therapeutics |
Conjugates of a lysosomal enzyme moiety and a water soluble polymer
|
CN102686606A
(zh)
*
|
2009-10-09 |
2012-09-19 |
阿纳福公司 |
结合il-23r的多肽
|
US20110086806A1
(en)
*
|
2009-10-09 |
2011-04-14 |
Anaphore, Inc. |
Polypeptides that Bind IL-23R
|
EP2805964A1
(de)
|
2009-12-21 |
2014-11-26 |
Ambrx, Inc. |
Modifizierte Rinder-Somatotropinpolypeptide und deren Verwendungen
|
NZ600363A
(en)
|
2009-12-21 |
2014-07-25 |
Ambrx Inc |
Modified porcine somatotropin polypeptides and their uses
|
JP6148013B2
(ja)
|
2010-03-05 |
2017-06-14 |
リグショスピタレト |
補体活性化のキメラ抑制分子
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
DK2605789T3
(da)
|
2010-08-17 |
2019-09-16 |
Ambrx Inc |
Modificerede relaxinpolypeptider og anvendelser deraf
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
AR087020A1
(es)
|
2011-07-01 |
2014-02-05 |
Bayer Ip Gmbh |
Polipeptidos de fusion de relaxina y usos de los mismos
|
GB201117428D0
(en)
*
|
2011-10-07 |
2011-11-23 |
Bicycle Therapeutics Ltd |
Structured polypeptides with sarcosine linkers
|
EP2606884A1
(de)
|
2011-12-21 |
2013-06-26 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Inhibitoren des Notch-Signalwegs und deren Verwendung bei der Krebsbehandlung
|
KR102172897B1
(ko)
|
2012-06-08 |
2020-11-02 |
서트로 바이오파마, 인크. |
부위-특이적 비-천연 아미노산 잔기를 포함하는 항체, 그의 제조 방법 및 그의 사용 방법
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
PL3584255T3
(pl)
|
2012-08-31 |
2022-05-16 |
Sutro Biopharma, Inc. |
Modyfikowane aminokwasy zawierające grupę azydkową
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US10093978B2
(en)
|
2013-08-12 |
2018-10-09 |
Genentech, Inc. |
Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
|
EP3055298B1
(de)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
|
CA2944712A1
(en)
|
2014-05-01 |
2015-11-05 |
Genentech, Inc. |
Anti-factor d antibody variants and uses thereof
|
UY36370A
(es)
|
2014-10-24 |
2016-04-29 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Polipéptidos fgf-21 modificados y sus usos
|
CA2989400A1
(en)
|
2015-06-15 |
2016-12-22 |
Angiochem Inc. |
Ang1005 for the treatment of leptomeningeal carcinomatosis
|
CN108472382A
(zh)
|
2015-10-30 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体变体缀合物及其用途
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
ES2963839T3
(es)
|
2017-02-08 |
2024-04-02 |
Bristol Myers Squibb Co |
Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
|
JP7441826B2
(ja)
|
2018-09-11 |
2024-03-01 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド抱合物およびその使用
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
JP2022520792A
(ja)
|
2019-02-12 |
2022-04-01 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用
|
EA202192394A1
(ru)
|
2019-04-10 |
2022-01-24 |
Селлестия Биотек Аг |
Ингибиторы пути передачи сигнала notch и их применение для лечения рака
|
CA3174114A1
(en)
|
2020-03-11 |
2021-09-16 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
CA3169967A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
JP2023538071A
(ja)
|
2020-08-20 |
2023-09-06 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲート、その方法及び使用
|
EP4255409A1
(de)
|
2020-12-07 |
2023-10-11 |
Cellestia Biotech AG |
Pharmazeutische kombinationen zur behandlung von krebs
|
EP4008324A1
(de)
|
2020-12-07 |
2022-06-08 |
Cellestia Biotech AG |
Kombinationen, die einen inhibitor eines anti-apoptotischen proteins, wie bcl-2, bcl-xl, bclw oder mcl-1, und einen notch-signalweg-inhibitor zur behandlung von krebs umfassen
|
CN112451681B
(zh)
*
|
2020-12-09 |
2023-08-25 |
苏州大学 |
酸敏感型聚合物-药物偶联物及其制备和应用
|
CA3213805A1
(en)
|
2021-04-03 |
2022-10-06 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|
WO2022253794A2
(en)
|
2021-06-02 |
2022-12-08 |
Cellestia Biotech Ag |
Method for treating an autoimmune and inflammatory disease
|
WO2023079132A1
(en)
|
2021-11-08 |
2023-05-11 |
Cellestia Biotech Ag |
Pharmaceutical combinations for treating cancer
|
EP4223292A1
(de)
|
2022-02-07 |
2023-08-09 |
Cellestia Biotech AG |
Pharmazeutische kombinationen zur behandlung von krebs
|